SCHEMBL23211834

SCHEMBL23211834

CC(C)(C)OC(=O)N1CCC(c2cc(Cl)cc(OCC(F)(F)F)c2)C1

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LIPE Q05469 1/20 0.46
PDE4B Q07343 1/20 0.46
STS P08842 3/20 0.42
TP53 P04637 3/20 0.42
MAPT P10636 2/20 0.42
P2RX7 Q99572 1/20 0.41
KDM4E B2RXH2 1/20 0.41
THRB P10828 1/20 0.41
DRD2 P14416 1/20 0.41
DRD3 P35462 1/20 0.41
LMNA P02545 1/20 0.41
TACR1 P25103 1/20 0.40
TRPV3 Q8NET8 1/20 0.40
EPHX2 P34913 1/20 0.39
DPP4 P27487 1/20 0.39
NR1D1 P20393 1/20 0.39
HPGDS O60760 1/20 0.38
ADAM17 P78536 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21381778 1.00 LIPE (0.46) LIPEPDE4BSTSTP53MAPT
SCHEMBL21381647 0.86 DRD2 (0.42) TP53MAPTDRD2DRD3LMNA
SCHEMBL23211945 0.86 DRD2 (0.42) TP53MAPTDRD2DRD3LMNA
SCHEMBL21381706 0.84 PDE4B (0.56) PDE4BSTSTP53MAPTKDM4E
SCHEMBL826363 0.84 PDE4B (0.56) PDE4BSTSTP53MAPTKDM4E
SCHEMBL30700870 0.84 LIPE (0.46) LIPESTS
SCHEMBL30700868 0.84 LIPE (0.46) LIPESTS
SCHEMBL29068340 0.82 PDE4B (0.48) PDE4BSTSTP53MAPTKDM4E
SCHEMBL19701837 0.78 ADAM17 (0.53) PDE4BSTSMAPTKDM4ETHRB
SCHEMBL23411133 0.77 LIPE (0.57) LIPEMAPTKDM4ETHRBEPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111936503-B Oxazine monoacylglycerol lipase (MAGL) inhibitors 豪夫迈·罗氏有限公司 2023-09-12 CN disclosed
US-20230117324-A1 OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS HOFFMANN-LA ROCHE INC. (US) 2023-04-20 US disclosed
EP-3768684-B1 OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS HOFFMANN LA ROCHE (CH) 2023-02-22 EP disclosed
US-20210107920-A1 OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS HOFFMANN-LA ROCHE INC. (US) 2021-04-15 US disclosed
CN-111936503-A Oxazin monoacylglycerol lipase (MAGL) inhibitors 豪夫迈·罗氏有限公司 2020-11-13 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210107920-A1 OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS MGLL, LPL, LIPC LIPE 6/4885PDE4B 1379/4885STS 388/4885
US-20230117324-A1 OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS MGLL, LPL, LIPC LIPE 6/4885PDE4B 1379/4885STS 388/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.